Methylation of HOXA9 was found positive in 80.0% (16/20) patients with stage I/II cancer, 81.5% (44/54) of stage III, and 90.9% (10/11) of stage IV ovarian cancer patients. Here, HOXA9 is linked to ovarian carcinoma.